Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
about
Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabOptimizing biologic treatment in IBD: objective measures, but when, how and how often?Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology PerspectivePotential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Conventional drug therapy for inflammatory bowel disease.Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Positioning Therapy for Ulcerative Colitis.Optimizing pharmacologic management of inflammatory bowel disease.Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel DiseaseAdvances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.Clinical performance of an infliximab rapid quantification assay.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysThe Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World ExperienceSerum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease.Subsequent entry biologics - opportunities and challenges.Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab.Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
P2860
Q26750456-B75AF008-54F5-451D-A3D9-C3C38E2286AAQ26775064-D32C3469-63F6-4DFE-8977-94DADEBC694FQ33874790-B1C13A65-2BB7-4279-834A-0AEF7CB9FFE6Q35670680-E7CCFD8D-220C-4A1C-AD65-33B33225A0FDQ36653930-D6396540-A449-4685-8AEB-DB6B35606995Q37729846-6FD7E6BF-21EE-49E6-97FA-2664DB5C1C8BQ38151885-0140B598-5F1F-48AD-87D7-C7389933E1FDQ38176154-D57E9B4B-4856-41B4-8AAE-9F690558DAB8Q38293796-226D37AB-2978-4865-98A9-D03B473319D2Q38337716-66223C4C-B9BD-441C-B2CE-5CF5B928B551Q38365049-410308A6-2291-43AE-B704-F1A9A7BD1EC0Q38462602-831C4625-F9A4-44A4-B827-64D22F2CF4FAQ38492052-E4311C9F-2E89-46BD-A712-379D1035B990Q38537167-5D246C7C-EB36-4D5A-96EF-1C2B0F32325BQ38542903-CC0D6B3B-A7B0-4989-8A82-54AD372B49B9Q38687407-267719ED-0B89-4036-A751-0E4CA4E70340Q38695700-E41BBC34-DD44-4E1B-B0C5-BBBCC72D7542Q38723611-4333D17D-80D9-479E-BC6F-46161B6C144BQ38822920-07203398-D4D3-491C-9928-E49044387FABQ38826447-A35EB3A3-883E-4701-BF4E-36300C2BEBBCQ38856947-B2F19B6F-195B-4DFF-BE1D-DB684E039918Q38923616-E8FF132C-F24B-4A82-A924-AA74E8148A04Q39681190-6BAD0B04-A766-48FB-8F74-E625BA008E84Q40624064-893A889A-0C41-4320-B373-D9422A34D09BQ41078459-31228994-BB05-4C74-A8F4-70E6F2C9BB38Q41078498-F2BF9DFC-4A28-434F-A6A9-5FD8BC2F1793Q42000636-BE15C824-D5AD-423F-AE17-2615CBC41179Q42293326-7DCA34FE-9071-4632-A857-977120B2E2A0Q42332335-C0E212D8-1AF0-416D-988F-7D5CCBA10B8AQ42373188-DFCAE1B7-58C8-42E4-A32B-26B400D31B5AQ42374439-5CA27500-B994-491B-AE94-EF182FD9EC15Q42938420-B9CD5446-3125-48A9-B32D-AA9C8E2C6F8AQ43190589-B46A2416-BAE1-4C01-B7FE-BCDE9556C22CQ47422402-CB63579D-8F36-43ED-9E39-D3367E9ADC77Q47438996-2E6A64FC-1525-4712-858B-2C052812EB0CQ47592530-38ECDD80-2BFE-4D1D-8F64-D0554ACA584DQ48144954-B32EF847-D8EB-434A-AA86-6875E8A72B8DQ50960517-0ED6BE2C-9E87-4954-A8EA-922BA1A14B1C
P2860
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Review article: a clinician's ...... in inflammatory bowel disease.
@en
type
label
Review article: a clinician's ...... in inflammatory bowel disease.
@en
prefLabel
Review article: a clinician's ...... in inflammatory bowel disease.
@en
P2093
P2860
P50
P356
P1476
Review article: a clinician's ...... in inflammatory bowel disease
@en
P2093
A H Steinhart
B Bressler
B D Sattin
B G Feagan
E G Seidman
E-J Bernard
G R Greenberg
G Van Assche
J K Marshall
P2860
P304
P356
10.1111/APT.12407
P407
P577
2013-07-14T00:00:00Z